Brain median Dice
0.96 DSC
- EndpointBrain segmentation
- PopulationLumiNE US; Lumi
- Tested versionLumiNE US / Lumi cleared in K240094
FDA-cleared profile
Augmedit B.V. · Radiological images; modality varies or is not specified in FDA list · FDA-cleared (510(k))
Authorized purpose: LumiNE converts adult CT or contrast-enhanced T1 MR images into reviewed three-dimensional models and displays two- and three-dimensional images in a browser or Microsoft HoloLens 2 for preoperative planning, not diagnosis.
Overview status: Source-reviewed overview
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
Clinical takeaway. Clinical role: LumiNE converts adult CT or contrast-enhanced T1 MR images into reviewed three-dimensional models and displays two- and three-dimensional images in a browser or Microsoft HoloLens 2 for preoperative planning, not diagnosis.
Evidence takeaway. Evidence from the reviewed source record: Exact-submission U.S. testing used independent expert-truthed MR cases. Median Dice and 95% Hausdorff results met prespecified criteria for brain, skin, tumor, and ventricles; subgroup findings directly produced the single-tumor size limits. A later phantom crossover study is product-family workflow evidence only.
Evidence context not reviewed for this FDA record.
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Clinical-use display mirrors the exact FDA-supported purpose reconciled from the decision-summary packet.
Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
Evidence
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Sensitivity is not the primary applicable endpoint for this acquisition, reconstruction, segmentation, planning, guidance, or dose-delivery function. Use the task-specific endpoints and tested population reported below.
Specificity is not the primary applicable endpoint for this acquisition, reconstruction, segmentation, planning, guidance, or dose-delivery function. Use the task-specific endpoints and tested population reported below.
0.96 DSC
0.99 DSC
0.93 DSC
0.89 DSC
5.88 mm
3.36 mm
2.85 mm
1.93 mm
K240094
Manufacturer evidence submitted for substantial equivalence; local clinical, technical, and workflow acceptance remains necessary.
PMC12743098
Product-family workflow evidence in a simulated setting, not clinical outcome evidence.
Safety and lifecycle
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
A zero-result exact-identifier search does not prove that no recall, correction, adverse-event report, or product-family safety signal exists.
Price not public here; enter your quote
Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.
No separate named-product payment identified in reviewed public material
Centers for Medicare & Medicaid Services · United StatesBuild a local total-cost and value model; do not infer reimbursement from FDA clearance.
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Source context, not route validation: Adult CT or contrast-enhanced T1 MR DICOM images; STL models can be associated with the source scan in supported workflows.
Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
Confirm scanner/model, protocol, series completeness and both software builds.
Field checked 2026-09-19 · FDA K240094: LumiNE US; Lumi
Source context, not route validation: DICOM and supported STL ingestion with browser and HoloLens 2 visualization; test scanners, DICOM variants, dimensional fidelity, latency, and export or revision behavior.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Field checked 2026-09-03 · FDA K240094: LumiNE US; Lumi · LumiNE FDA clearance announcement · Mixed-reality preoperative planning with Lumi in a phantom crossover study
Source context, not route validation: Secure cloud storage and browser-based viewer with optional Microsoft HoloLens 2, as described in K240094.
Scope: Exact FDA submission.
Confirm processing location, queue ownership, exclusions and exact AI build.
Field checked 2026-09-03 · FDA K240094: LumiNE US; Lumi · LumiNE FDA clearance announcement · Mixed-reality preoperative planning with Lumi in a phantom crossover study
Source context, not route validation: Reviewed 3D models of skin, brain, tumor, and ventricles plus 2D/3D browser or HoloLens visualization.
Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Field checked 2026-09-19 · FDA K240094: LumiNE US; Lumi
Unresolved route: Reviewed 3D models of skin, brain, tumor, and ventricles plus 2D/3D browser or HoloLens visualization.
Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Field checked 2026-09-19 · FDA K240094: LumiNE US; Lumi
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
No tests below have been performed or accepted.
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
Confirm the controls against the exact contracted architecture and release.
Map the installed model, build, options, population, anatomy, inputs, and outputs to K240094 before acceptance.
exact submission · checked 2026-09-03Later product-family features are not evidence that this cleared release includes them.
DICOM and supported STL ingestion with browser and HoloLens 2 visualization; test scanners, DICOM variants, dimensional fidelity, latency, and export or revision behavior.
exact submission · checked 2026-09-03Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.
Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. Not for diagnosis. MR tumor segmentation is restricted to a single previously diagnosed contrast-enhancing intracranial tumor from 2-100 cc and 15-75 mm; multiple lesions and tumors outside those bounds were not adequately validated.
exact submission · checked 2026-09-03Define stop-use, escalation, rollback, and revalidation triggers before production use.
Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.
product family · checked 2026-09-03Vendor productivity claims are scenario inputs, not guaranteed local savings.
Monitor by exact hardware, software and model version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track the limits that matter for this product: Not for diagnosis. MR tumor segmentation is restricted to a single previously diagnosed contrast-enhancing intracranial tumor from 2-100 cc and 15-75 mm; multiple lesions and tumors outside those bounds were not adequately validated.
exact submission · checked 2026-09-03Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes.
Regulatory identity
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
The exact indication specifies MRI and/or CT imaging of adult patients; it does not support the broader directory-style modality value. Controlled directory display reconciled from exact FDA wording: Magnetic Resonance Imaging (MRI) and/or Computed Tomography (CT) imaging of adult patients. -> Radiological images; modality varies or is not specified in FDA list.
Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
Research record
This audit distinguishes completed source review from fields that have not yet been researched.
The refreshed discovery snapshot contains 20 PubMed and 10 ClinicalTrials.gov candidate records. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 20 PubMed and 10 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, vendor product page, peer reviewed publication, reimbursement policy, fda device recall, fda decision summary packet, literature index, trial registry, pubmed, clinical trials, openfda device recall
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, enabled features, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.
8 sources - 3 history items
Scope: purpose, anatomy, intendedUsers, input, output, limitations, modality, evidenceSummary, clinicalUse
Scope: regulatoryIdentity, modalityContext
Scope: evidenceDiscovery
Scope: evidenceDiscovery, studyStatus
Scope: coverage, codingContext
Scope: recallDiscovery, nativeSubmissionMatching
Scope: productFamily, workflowRole, deployment, implementationCapabilities, currentCommercialContext
Scope: limitations, evidenceSummary, evidenceStudy, implementationCapabilities, monitoring
Regulatory record
510(k)
Research record
fda record reviewed
Editorial review
Source-reviewed editorial overlay
Alternatives
Surgical Information Sciences, Inc.
Authorized purpose: SIS System version 5.6.0 fuses clinical brain MRI with postoperative CT for DBS anatomy visualization and implanted-lead placement localization, including STN, GPe, and GPi.
Surgical Information Sciences, Inc.
Authorized purpose: SIS System version 5.1.0 processes and fuses brain MRI and CT for DBS surgical planning and visualization of STN, GPe, and GPi anatomy.
Surgical Information Sciences, Inc.
Authorized purpose: SIS Software v3.6.0 displays, presents, documents, registers, fuses, and processes brain MR and postoperative CT images to support stereotactic neurosurgery and subthalamic-nucleus visualization.
Surgical Information Sciences, Inc.
Authorized purpose: SIS Software v3.3.0 fuses clinical brain MRI with postoperative CT to visualize and localize the subthalamic nucleus and support stereotactic surgical planning.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Open existing correction destinationPermission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.
Correction policy and limits · Public repository change history